Expression of functional neuronal receptor latrophilin 1 in human acute myeloid leukaemia cells

• Published in: Oncotarget Vol. 7; no. 29; pp. 45575 - 45583
• Main Authors: Sumbayev, Vadim V, Gonçalves Silva, Isabel, Blackburn, Jennifer, Gibbs, Bernhard F, Yasinska, Inna M, Garrett, Michelle D, Tonevitsky, Alexander G, Ushkaryov, Yuri A
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 19.07.2016
• Subjects: Biomarkers, Tumor - analysis; Humans; Leukemia, Myeloid, Acute - metabolism; Receptors, G-Protein-Coupled - biosynthesis; Receptors, Peptide - biosynthesis; Research Paper; Tumor Cells, Cultured; latrophilin; mammalian target of rapamycin; myeloid leukaemia
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.10039

Acute myeloid leukaemia (AML) is a blood cancer affecting cells of myeloid lineage. It is characterised by rapid growth of malignant leukocytes that accumulate in the bone marrow and suppress normal haematopoiesis. This systemic disease remains a serious medical burden worldwide. Characterisation of protein antigens specifically expressed by malignant cells, but not by healthy leukocytes, is vital for the diagnostics and targeted treatment of AML. Here we report, for the first time, that the neuronal receptor latrophilin-1 is expressed in human monocytic leukaemia cell lines and in primary human AML cells. However, it is absent in healthy leukocytes. Latrophilin-1 is functional in leukaemia cells tested, and its biosynthesis is controlled through the mammalian target of rapamycin (mTOR), a master regulator of myeloid cell translational pathways. Our findings demonstrate that latrophilin-1 could be considered as a novel biomarker of human AML, which offers potential new avenues for AML diagnosis and treatment.